Israel-Medical-Healthcare

[genisi]

Evolution: ORTX.OB-PXTB.OB-PLX

Protalix BioTherapeutics, Inc. to Commence Trading on the American Stock Exchange
Fri Mar 9, 7:05 AM

CARMIEL, Israel, March 9 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (OTC Bulletin Board: PXBT.OB) today announced that its common stock has been approved for listing on the American Stock Exchange. Protalix's common stock is expected to commence trading on the American Stock Exchange under the ticker symbol PLX on Monday, March 12, 2007. Protalix has selected Weiskopf Silver & Co. as its specialist.

David Aviezer, Ph.D., President and CEO of Protalix said, "This listing represents a significant milestone for Protalix following the completion of our merger with Orthodontix, Inc. We believe that listing our shares on the American Stock Exchange will provide us with an effective outlet through which to communicate continued progress in our clinical development and the anticipated commercialization of our products under development."

Dr. Aviezer added, "I am confident that our listing on a national stock exchange will benefit our shareholders through improved visibility and liquidity for our shares. We are pleased to have qualified for this listing, and look forward to a long and mutually beneficial relationship with the American Stock Exchange."

This approval is contingent upon Protalix being in compliance with all applicable listing standards on the date it begins trading on the Exchange, and may be rescinded if Protalix is not in compliance with such standards.

About Protalix BioTherapeutics, Inc.